OOIL, NVSR, ACCP, BBYB, ALRX, RSGR, BZCN, HTDS, CBIS, GDSM, IDOI Daily Market Movers Digest Midday Report for Monday, July 27th from OTCPicks.com
Our Stocks to Watch today include OriginOil Inc. (OTCBB: OOIL), NavStar Technologies Inc. (OTC: NVSR), Access Pharmaceuticals Inc. (OTCBB: ACCP), Baby Bee Bright Corp. (OTC: BBYB), AlphaRx Inc. (OTCBB: ALRX), Resource Group International Inc. (OTC: RSGR), BizAuctions Inc. (OTC: BZCN), Hard to Treat Diseases Inc. (OTC: HTDS), Cannabis Science Inc. (OTCBB: CBIS), Gold Coast Mining Corp. (OTC: GDSM) and IDO Security Inc. (OTCBB: IDOI).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.
ORIGINOIL INCORPORATED (OTCBB: OOIL)
"Up 4.97% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/OOIL.php
Company Profile: http://www.otcpicks.com/originoil.htm
OriginOil, Inc. is developing a breakthrough technology that will transform algae, the most promising source of renewable oil, into a true competitor to petroleum. Much of the world's oil and gas is made up of ancient algae deposits. Today, our technology will produce "new oil" from algae, through a cost-effective, high-speed manufacturing process. This endless supply of new oil can be used for many products, such as diesel, gasoline, jet fuel, plastics and solvents, without the global warming effects of petroleum. Other oil-producing feedstock, such as corn and sugarcane, often destroy vital farmlands and rainforests, disrupt global food supplies and create new environmental problems. Our unique technology, based on algae, is targeted at fundamentally changing our source of oil without disrupting the environment or food supplies.
OOIL News:
July 27 - OriginOil Announces Breakthrough Process for Live Algae Oil Extraction
Algae ‘milking’ promises new efficiencies as part of a combined production cycle
OriginOil, Inc. (OTCBB: OOIL), the developer of a breakthrough technology to transform algae, the most promising source of renewable oil, into a true competitor to petroleum, announced that it has succeeded in extracting algae oil on a continuous basis without cell sacrifice. This new ‘milking’ process will join the company’s Cascading Production™ technique to create a combined cycle promising new efficiencies.
Live Extraction™, or milking, is inherently efficient because it achieves continuous production of algae oil without destroying the algae cell. Therefore a single algae cell can produce more oil during its lifetime using lower amounts of energy. Unlike other approaches to live extraction, OriginOil’s process does not employ expensive consumables such as reverse osmosis membranes; furthermore, it is not limited to oil-bearing algae strains, such as Botryococcus braunii, that are known to excrete algae oil naturally.
Algae typically protect their oil behind a tough cell wall. The challenge of live extraction is to harvest the oil without causing permanent damage to the cell. This goal has been achieved in the laboratory at bench scale and is now being scaled up to OriginOil’s intermediate 200-gallon tank size. A diagram illustrates the process at www.originoil.com/technology/live-extraction.html.
The company recently filed for patent protection of the new Live Extraction process, its ninth patent application, entitled “Procedure for Extraction of Lipids from Algae without Cell Sacrifice.” “Live Extraction works by stimulating the algae cells through specific electrical modulations,” Riggs Eckelberry, OriginOil’s CEO, said. “The challenge is how to keep the cells alive while continuously extracting the oil, and we have achieved this.”
“We are pleased with the results we are getting from conventional harvesting,” said Vikram Pattarkine, PhD, OriginOil’s CTO. “We expect the new Live Extraction process to coexist with our daily ‘destructive’ process to create an even more efficient combined cycle.”
Aside from any production gains, combining the two processes is desirable because algae cultures must be refreshed regularly to remove waste toxins. Cascading Production supports Live Extraction by removing a percentage of the culture every day, refreshing the environment and giving the algae culture space to grow.
Following Exxon Mobil’s recent announcement of a $600 million investment in San Diego- based Synthetic Genomics, Paul Reep, senior technical adviser and one of the inventors, noted: “Live lipid extraction is especially beneficial when used with algae that have been genetically engineered for faster growth rate or higher lipid yields. By integrating Live Extraction into our process, we are providing a technology platform for companies like Synthetic Genomics that are experimenting with genetic improvements.”
OriginOil Inc.'s Technology Update Prompts Updated Rating by BeaconEquity Research
OriginOil Inc. (OTCBB: OOIL) receives updated Speculative Buy from Beacon Analyst Victor Sula, Ph.D., fueled by the Company’s recent patent applications for its “milking” process to extract algae oil, a patent filing for its Dynamic Control System, and its application or a Patent Cooperation Treaty for low-energy, high-efficiency algae production.
The full report is available at http://www.beaconequity.com.
Anyone interested in receiving alerts regarding OOIL research should e-mail members@beaconequity.com with “OOIL” in the subject line.
In the report, the analyst writes:
“The renewable energy sector has already recognized the potential of algae as a feedstock to replace soybean, rapeseed and corn in biofuel production. … Because of these advantages, we expect larger-scale production of algae and/or algae-biomass products over the next five years.
“Robust clean energy demand, OOIL’s progress in advancing its proprietary algae biofuel technologies and the significant future revenue potential associated with licensing this technology to biofuel manufacturers and refiners are reasons we continue to rate OOIL a Speculative Buy.”
Other companies in the research services industry include: Nanoforce Inc. (OTC: NNFC), PetroSun Inc. (OTC: PSUD), Green Star Products Inc. (OTC: GSPI) and Valcent Products Inc. (OTCBB: VCTPF).
NAVSTAR TECHNOLOGIES INCORPORATED (OTC: NVSR)
Detailed Quote: http://www.otcpicks.com/quotes/NVSR.php
Company Profile: http://www.otcpicks.com/navstar-technologies/navstar-technologies.htm
NavStar is focused on the creation of GPS products and services that provide wireless tracking of vehicles, equipment, and other valuable and personal assets. The goal is to be a total solutions provider.
NVSR News:
July 22 - Vehicle/Asset Tracking Forecast to Grow From $3.0B to $5.0B by 2011
NavStar Technologies, Inc. (OTC: NVSR), a multinational firm focused on developing and commercializing asset tracking and monitoring devices for vehicles and high value cargo with specific geographic focus in Latin America, has made available to shareholders and investors an independent research report on Vehicle/Asset tracking and monitoring.
According to the report, adoption of vehicle/asset tracking and monitoring is likely to be driven by factors such as:
* Increased recognition of tracking/monitoring benefits
* Worker productivity
* Administrative efficiency
* Reliable and affordable data communications
* Increase availability of wireless coverage
The report says that today only 10% of the 20M fleet vehicles in the
N. Douglas Pritt, Chairman and CEO, confirmed that NavStar's business model for sales into
NavStar also re-affirmed guidance regarding its expected financial performance over the next 5 years. The successful achievement of these financial objectives assumes the company's procurement of up to $2.0 million of funding in the 3rd quarter of this year and the completion of the services/software company.
N. Douglas Pritt, Chairman and CEO, said, "We continue to stay focused on getting POs from our distribution partners in
For the complete research report, go to www.navstarinc.com and click the "What's New" link.
ACCESS PHARMACEUTICALS INCORPORATED (OTCBB: ACCP)
"Up 19.48% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ACCP.php
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.
ACCP News:
July 27 - Access Pharmaceuticals Announces Commercial Launch of MuGard™ in
Early Market Assessment Studies Suggest Larger Market Potential
Access Pharmaceuticals, Inc. (OTCBB: ACCP) announced that its European partner, SpePharm, has commenced commercial launch of MuGard in
Central to the MuGard commercial launch strategy is a coordinated effort to seek reimbursement from governmental agencies, placement in pharmacy formularies and an aggressive seeding strategy in leading cancer treatment centers and with leading clinicians. Aggressive sampling and education of patients and clinicians on early prophylactic use is proving important in reducing incidence, severity and duration of oral mucositis.
"The early feedback includes a high rate of enthusiasm and intention to continue use by practicing clinicians and patients, who have used MuGard," stated Jeffrey B. Davis, Access' President & CEO. "We believe this enhanced awareness of the benefits associated with use of MuGard as a preventative treatment is likely to result in solid marketing traction and market penetration in
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion world-wide.
MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.
BABY BEE BRIGHT CORPORATION (OTC: BBYB)
Detailed Quote: http://www.otcpicks.com/quotes/BBYB.php
Company Profile: http://www.otcpicks.com/baby-bee-bright/baby-bee-bright.htm
Baby Bee Bright Corporation manages the Baby Bee BrightTM brand. Its executive staff, composed of professionals with over 30 years of experience in engineering research and marketing, have developed an innovative prenatal communication system, servicing the rapidly expanding expectant mother/prenatal market. The company has a patented, audio directional technology for its communicator which is designed for expectant mothers to safely and efficiently transmit music and sound to their babies. It allows mothers and family to bond with their babies before birth. Lullabies and classical music provide the baby with soothing sounds before and after birth.
BBYB News:
July 20 - Baby Bee Bright Targets
Baby Bee Bright Corporation (OTC: BBYB), developer of a unique prenatal communication system, is expecting a marked increase in sales in the United Kingdom as a result of the release of the publication, “You and Your Family.” Considering the fact that the shipping cost from the
Fred Dahlman, CEO, stated, “Baby Bee Bright is ready to find distribution centers in the
ALPHARX INCORPORATED (OTCBB: ALRX)
"Up 6.90% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ALRX.php
Company Profile: http://www.otcpicks.com/alpharx/alpharx.htm
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.
ALRX News:
July 23 - AlphaRx Presents Positive Preclinical Data on Zysolin™ Inhalable Nanoparticles at Controlled Release Society Annual Meeting
AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results which demonstrated that an inhaled tobramycin nanoparticle (Zysolin) formulation was a more effective treatment in animal models of acute Pseudomonas aeruginosa pneumonia when compared to inhaled and injected conventional tobramycin solutions. The data was presented recently in an oral podium session at the 36th Annual Meeting and Exposition of the Controlled Release Society in
"These are very encouraging results, as they suggest that Zysolin employed in this route of administration may be more effective, providing significant advantages over conventional drug formulations," stated Joseph Schwarz, Ph.D., Chief Scientist of AlphaRx. "We believe that building on this data, additional research will lead us toward the development of a drug that targets and eradicates intracellular pathogens, which to date, have proven to be very difficult to treat clinically."
The study results demonstrate that Zysolin is significantly efficacious in acute pneumonia animal models induced by gram negative pathogens including P. aeruginosa. In these lethality-based studies, Zysolin consistently increased survival rate to 50% over a Tobramycin treatment group, wherein all untreated animals died within 24 hours after infection. P. aeruginosa is one of the most common and lethal pathogens responsible for ventilator-associated pneumonia in intubated patients, being directly responsible for death rates approaching 40%. This data suggests that the nanoparticulate formulation of Zysolin may utilize a unique mechanism of action differentiating it from conventional formulations, enhancing antimicrobial activity against gram negative pathogens. Zysolin has the potential to be a first-in-class anti-infective nanomedicine.
The Controlled Release Society (CRS) is an international organization consisting of 3,000 members from more than fifty countries. Two-thirds of CRS membership are from the pharmaceutical industry and one-third consist of academic and government members. The CRS is the premier multidisciplinary society dedicated to the promotion of the science, technology, and innovative delivery of bio-actives for the benefit of the society.
ABOUT ZYSOLIN™
Zysolin is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin improves the intracellular activity of Tobramycin — in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin, Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin.
RESOURCE GROUP INTERNATIONAL INCORPORATED (OTC: RSGR)
"Up 50.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/RSGR.php
Resource Group International is a multi-faceted corporation that is developing businesses in the energy, power and food sectors around the world. Resource Group specialized in the research, discovery, development and commercialization of proprietary technologies that will enhance the production and efficiency of business in the energy and food sectors. Resource Group's goal and vision is to become a major player and the world's leading developer of breakthrough products in the energy, power and food businesses.
RSGR News:
July 27 - Resource Group Announces Its Planned Entry Into the Enhanced Oil Recovery Market in
Resource Group International Inc. (OTC: RSGR), a leading global provider of a patented steam generated enhanced oil recovery technology for extraction of heavy oil for secondary oil recovery, announced the Company has entered preliminary verbal discussions with a major oil producer in Brazil. The verbal agreement includes terms whereby Resource Group will joint venture with Brazil-Co to utilize its EOR technology on some of its less productive wells.
The joint venture has agreed to test the technology on several wells and if the results are as we anticipate, then the EOR technology will be expanded to include all of the wells that Brazil-Co has that can benefit from the use of EOR methods. There are over 13,000 wells in
"This is the first of what we anticipate is many international business relationships that we will be working towards in the coming months and years ahead. With EOR opportunities on every continent in the world and 10s of thousands of potential wells as targets, the revenues and profits projections are astronomically huge for us," stated Gregory J. Curry, President and CEO.
BIZAUCTIONS INCORPORATED (OTC: BZCN)
"Up 23.81% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BZCN.php
BizAuctions, Inc. is a prime provider of commercial eBay liquidation services for excess inventory, overstock items, and returns. Our clients have included some of the Nation's leading retail names at the forefront of their industries. BizAuctions addresses the $60 billion excess inventory problem for clients by sending trucks to pick up pallets of excess inventory, selling the inventory on eBay, and collecting payment. We provide our clients with a new sales channel to generate additional revenue on excess inventory, while at the same time freeing up their valuable storage and retail space. With a long-term strategy to provide eBay liquidation services to Fortune 1000 enterprises, BizAuctions is a clear and lucrative solution for most any business to liquidate its excess inventory on eBay.
BZCN News:
July 23 - BizAuctions' Retail Store Gaining Sales in 7th Week of Operations
BizAuctions, Inc. (OTC: BZCN), a prime provider of commercial eBay liquidation services for excess inventories, overstocks, and returns, announced today that its recently opened retail clothing store, Lucky 7's, continues to gain sales on a weekly basis after its seventh full week of retail operations.
"Lucky 7's is in its seventh full week of retail operations and sales have continued to increase weekly since the opening of the store on May 29, 2009. We are building a solid base of repeat customers and are continuing to see new customers looking for great buys on our name brand clothing and merchandise," noted Delmar Janovec, BizAuctions, CEO.
Janovec added, "Lucky 7's customer base is building by word-of-mouth from its repeat customers as minimal amounts have been spent for advertising. If our retail operations are as successful as we plan, we should see additional revenue growth while providing our customers with name brand products at reasonable prices."
BizAuctions' clients have included some of the Nation's leading retail names at the forefront of their industries. With a long-term strategy to provide eBay liquidation services to Fortune 1000 enterprises, BizAuctions is a clear and lucrative solution for most any business to liquidate excess inventory on eBay.
HARD TO TREAT DISEASES INCORPORATED (OTC: HTDS)
"Up 54.55% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/HTDS.php
In June 2003, International Foam Solutions, Inc. changed its name to Hard to Treat Diseases, Inc. in connection with the completion of a share exchange agreement with Hard to Treat Diseases and T-19, Inc. Hard to Treat Diseases, Inc. holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating cancer and rheumatoid arthritis under medical patent. Tubercin promotes good health by enhancing the immune system. The nasal spray would be distributed through major holistic retailers and providers worldwide.
HTDS News:
July 23 - Hard to Treat Diseases, Inc. Reports on Ribavirin Research as Potential Treatment for MS
Hard to Treat Diseases, Inc. (OTC: HTDS) reports that researchers in its Slavica BioChem division have advised of some significant findings regarding its research into the use of Ribavirin in the treatment of Multiple sclerosis (MS).
The research team has been conducting experiments using Dark Agouti rats. Experimental autoimmune encephalomyelitis (EAE) induced in susceptible strains of animals provides the best available model for studying events in MS and a helpful tool in preclinical testing of various substances considered for treatment of the central nervous system (CNS) disease. CNS is the part of the nervous system that functions to coordinate the activity of all parts of the bodies of multicellular organisms.
In summary, these findings suggest that Ribavirin attenuates experimental autoimmune encephalomyelitis (animal model of multiple sclerosis) by limiting cytokine-mediated immuno-inflammatory events that lead to CNS destruction.
The conducted experiments provide rationale for ribavirin to be considered as a candidate drug in the development of new therapeutic strategies for the treatment of autoimmune diseases in humans, such as multiple sclerosis. One of the benefits of working with established drugs such as ribavirin, which has been in use approximately twenty years, is that the significant experience and history of the drug make it easier to obtain approval for use in new applications, such as the research that has been conducted by Slavica BioChem.
Dr.Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem said "We are proud to be part of the Hard to Treat Diseases and we are grateful for the funding our division has received. This is of great assistance for continuing of our experiments. We have already ordered some chemicals and antibodies with the funding received. This has afforded us an opportunity to straighten our equipment and to introduce a new methodological approaches and techniques (like PCR and RT-PCR) that would give added value to our research".
Mr. Terry Yuan CEO said, "There is great synergy between the two companies Slavica BioChem and Mellow Hope. Although Slavica currently has no revenues, their developmental and research contributions have the potential to transform into enormous and massive gains for HTDS and its shareholders. We expect to be releasing HTDS Q2 financials shortly, and some positive updates on the IP issue very shortly.
CANNABIS SCIENCE INCORPORATED (OTCBB: CBIS)
"Up 60.58% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CBIS.php
Cannabis Science Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
CBIS News:
July 24 - CNN Pandemic Report on H1N1 Pushes Cannabis Science to Move Faster to Release Its Anti-Inflammatory Cannabis Drug as Similarities Between 2009 and Deadly 1918 Influenza Pandemic Cause Concern; FDA Approved Drugs Needed Now to Meet This Urgent Situation
Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company, is making its anti-inflammatory formulation that targets influenza symptoms one of its top priority drugs to release, as the latest Swine flu numbers are rapidly increasing and have become quite alarming. Research indicates that the current H1N1 influenza virus has disturbing similarities to the 1918 pandemic, which killed tens of millions after World War I. Moreover, the young and otherwise healthy population that has been most susceptible to the H1N1 virus is a similar demographic to those most affected in the 1918 outbreak.
Swine flu, Bird Flu and all influenza strains that elicit excessive inflammatory immune response are targeted with Cannabis Science formulations. The company is developing its strategy for studying the effects of its cannabis lozenge on influenza deaths that are associated with an excessive inflammatory response. A hyper-inflammatory response appears to be the cause of the high mortality (63%) associated with the Avian flu (H5N1), and recent studies indicate a similar risk with the Swine flu (H1N1) as well. The World Health Organization (WHO) released the latest figures and said the virus was "unstoppable" and had become widespread enough to raise the global Swine flu alert to its highest level.
Dr. Robert Melamede, Ph.D., Cannabis Science Inc. President & CEO, observed, "Contemporary anti-viral medical technology is currently inadequate to meet the World's immediate challenges in dealing with the rapid mutations and infectivity of the numerous influenza viruses. We believe that cannabis extract-based medicines can reduce influenza deaths, and allow infected individuals to develop a strong natural immunity upon recovery."
Specifically, Cannabis Science Inc. believes that its whole-cannabis extract lozenge will inhibit the development of ARDS (Adult Respiratory Distress Syndrome) associated with deaths from both the Avian and Swine influenza infections. Dr. Melamede believes there is enormous potential value for cannabinoids that naturally prevent excessive inflammatory immune responses. He stated, "Based upon recent discoveries regarding the role that endocannabinoid system plays in maintaining human health, we may have a unique solution to the looming threat posed by deadly influenza strains, which we believe, if implemented, could save millions of lives."
Previously, Dr. Melamede urged all cannabis consumers, "If you come down with the flu, cease smoking and switch to edibles. We believe that smoking marijuana when a person has influenza will lead to some unnecessary deaths, whereas eating it can prevent unnecessary deaths."
GOLD COAST MINING CORPORATION (OTC: GDSM)
"Up 4.35% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/GDSM.php
Gold Coast Mining Corp. is pursuing mining acquisitions and joint ventures. The Company currently has a joint venture with Western Sierra Mining Corp. for its Ore Cache and SunGold Mines located in
GDSM News:
July 23 - Gold Coast Mining Announces Corporate Update
Gold Coast Mining Corp. (OTC: GDSM), announced the following corporate update:
Over the last several months the Company has completed numerous tasks in its effort to restore shareholder value. The name change, execution of a joint venture agreement with Western Sierra Mining Corp. and the sale of 51% of the Hot Web domains to a soon to be publicly traded company are three of the major milestones that have been accomplished to date.
In addition, the Company recently added two mining executives to its advisory board and secured the domain www.goldcoastminingcorp.com. The Company has also secured a web designer and expects the corporate site to be completed shortly.
In regards to its joint venture with Western Sierra Mining Corp. ("WSM"), the Company is a 50% partner on two mines currently owned by WSM (the Ore Cache Mine and the SunGold Mine). WSM will mine the properties and the Company will receive a 50% share of the proceeds after extraction costs. For its share of the joint venture the Company has agreed to provide capital to WSM to fund initial expenses such as the construction of a hard rock free gold recovery plant.
The Company plans to continue to fund the joint venture through loans from current shareholders and with a portion of the shares currently owned in Max Media Group, Inc. ("MMG"). As previously announced, the Company owns 49% or 29,700,000 shares of MMG (owner of the Hot Web domain properties). MMG has completed its merger with a publicly traded company and is expected to be trading the beginning of August. MMG has arranged a private placement of 1,000,000 shares of MMG common stock at a purchase price of $0.50 per share with its current shareholders to fund the expansion and marketing of its domain properties (www.hotautoweb.com, www.hotboatweb.com, www.hotplaneweb.com, www.hotcharityweb.com, www.hotrvweb.com, www.hotcycleweb.com).
Although the exact dividend has not yet been determined, the Company intends to dividend to shareholders no less than 50% (14,850,000 shares) of the 29,700,000 shares of MMG it currently owns. Management expects the exact dividend and record date to be announced by the first week of August.
IDO SECURITY INCORPORATED (OTCBB: IDOI)
"Up 40.74% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/IDOI.php
IDO Security, Inc. engages in the design, development, and marketing of technology based security systems for the homeland security and loss prevention markets. Its products are used in security screening procedures and are designed to detect ferrous and non-ferrous metallic objects concealed on or in shoes, ankles, and feet through the use of electro-magnetic fields. The company offers MagShoe, which is used to detect metallic items during security screenings, as well as at security checkpoints in venues, such as schools, prisons, commercial aviation and maritime facilities, rail transportation, shopping centers/places of entertainment, business facilities bus and train stations, border crossings, government institutions/buildings, critical infrastructure, and defense facilities. IDO Security was founded in 2002 and is based in
IDOI News:
July 21 - IDO Security Brings Added Security to Major Government Buildings in
IDO Security, Inc. (OTCBB: IDOI) (www.idosecurityinc.com), developer of the innovative MagShoe™ “shoes-on” weapons metal detection system, today announced an order for MagShoe units from its Australian distribution partner, XTEK Limited, for distribution to Australia's Victoria Department of Justice. The units will be added to a number of MagShoe installations already in place at courthouses throughout
MagShoe is already well known throughout the Pacific Rim, and specifically in
"We continue to see an incredible need — one that is reinforced by our clients and partners in Australia, and around the world — for comprehensive, head-to-toe security screening," said Dan Werber, International Marketing Manager of IDO Security. "The MagShoe is the final piece to that puzzle, meeting the needs of government buildings, airports and other venues worldwide that demand the most stringent levels of security."
MagShoe extends the capabilities of today's security screening technologies to include the lower extremities — an area not effectively addressed by traditional walkthrough and handheld metal detectors. The portable, user-friendly device improves accuracy, reduces wait times and provides clear, immediate results.
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com previously compensated three thousand dollars by a third party (Blue Wave Advisors) for a one-week OOIL advertising and promotional program. In this OOIL promotional campaign OTCPicks is being compensated three thousand dollars by a third party (Blue Wave Advisors). OTCPicks.com has been compensated eight thousand dollars by a third party (Mickey Reno) for NVSR advertising and promotional services. OTCPicks.com has been compensated three thousand five hundred dollars by a third party (Longview Communications Corp.) for ACCP advertising and promotional services. OTCPicks.com has been compensated a total of two million free trading shares by a non-controlling third party (Microcap Management) for BBYB advertising and promotional services. OTCPicks.com has been compensated seven thousand five hundred dollars by a third party (Blue Wave Advisors) for ALRX advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
